BridgeBio Pharma’s Stock Price Expected to Reach $40.00 in One Year Despite Wednesday’s Dip
July 7, 2023
🌥️Trending News
BridgeBio Pharma Inc. has been making headlines recently as its stock price closed at $16.81 on Wednesday, July 05, which is 3.11% lower than its prior close.
However, despite the slight dip, analysts are still confident that the trading price of the company will surpass $40.00 in one year’s time. BRIDGEBIO PHARMA ($NASDAQ:BBIO) is a biopharmaceutical company focused on discovering, developing and commercializing transformative medicines in genetically-defined diseases. The company’s mission is to accelerate the development of breakthrough therapies for genetic diseases by connecting them to the resources of a leading-edge biopharmaceutical platform. By leveraging its proprietary technology platforms and deep expertise in gene and cell biology, the company is able to bring innovative treatments to patients rapidly and cost-effectively. It currently has several innovative programs in development targeting diseases such as cystic fibrosis, Huntington’s disease, and Duchenne muscular dystrophy.
Share Price
BridgeBio Pharma Inc.’s stock price is expected to reach $40.00 in one year, despite a 2.8% dip on Wednesday. On Thursday, BRIDGEBIO PHARMA stock opened at $17.2 and closed at $17.0, a decrease from the previous closing price of 17.5. This dip in price is not anticipated to have any long-term effects on the stock, and analysts expect that the stock will rise to reach $40.00 in the coming year. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Bridgebio Pharma. More…
| Total Revenues | Net Income | Net Margin |
| 77.78 | -424.94 | -514.9% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Bridgebio Pharma. More…
| Operations | Investing | Financing |
| -403.18 | 326.82 | 137.28 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Bridgebio Pharma. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 625.68 | 1.84k | -7.65 |
Key Ratios Snapshot
Some of the financial key ratios for Bridgebio Pharma are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 24.2% | – | -444.6% |
| FCF Margin | ROE | ROA |
| -525.4% | 17.4% | -34.5% |
Analysis
GoodWhale has conducted an analysis of the financials of BRIDGEBIO PHARMA and the results are not very encouraging. According to our Star Chart, BRIDGEBIO PHARMA has a low health score of 2/10. This indicates that it is less likely to pay off debt and fund future operations. Furthermore, the company is strong in growth but weak in asset, dividend, and profitability. We have classified BRIDGEBIO PHARMA as a ‘cheetah’, a type of company that has achieved high revenue or earnings growth but is considered less stable due to lower profitability. Given that BRIDGEBIO PHARMA is considered a ‘cheetah’, investors who look for high risk/high reward opportunities may be interested in this company. They may also be drawn to the potential growth that the company is capable of achieving if managed correctly. On the other hand, investors who prefer more stability may find this company too risky and opt to look elsewhere. More…
Peers
The competition among BridgeBio Pharma Inc and its competitors is fierce. All four companies are working to develop new and innovative treatments for various diseases and disorders. While each company has its own unique approach, they all share a common goal: to improve the lives of patients.
– Faron Pharmaceuticals Oy ($LSE:FARN)
Faron Pharmaceuticals Oy is a Finnish pharmaceutical company with a market cap of 148.02M as of 2022. The company’s Return on Equity is 1278.12%. Faron Pharmaceuticals Oy is engaged in the research and development of drugs for the treatment of cancer and other serious diseases. The company’s products include Traumakine, a drug for the treatment of traumatic brain injury, and Clevegen, a drug for the treatment of solid tumors.
– Trevi Therapeutics Inc ($NASDAQ:TRVI)
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of nalbuphine ER to treat serious and debilitating conditions. Its product candidate, Nalbuphine ER, is an opioid analgesic that is in the late-stage clinical development for the treatment of pruritus in adult patients with Atopic Dermatitis, and for the treatment of chronic pruritus in adult patients with renal impairment.
– IRLAB Therapeutics AB ($BER:6IRA)
Diaverum is a Swedish renal care company. The company provides dialysis, peritoneal dialysis, and kidney transplantation services through a network of clinics in Europe, Asia-Pacific, the Middle East, and Latin America. Diaverum is a publicly traded company with a market capitalization of 161.21 million as of 2022. The company has a return on equity of -19.31%.
Summary
Investing in BridgeBio Pharma has been seen as a potentially lucrative move for those looking to capitalize on the company’s stock. Analysts predict that the stock price of BridgeBio could climb past $40 in the next year. Despite the potential upside, the stock has recently seen a dip, closing at $16.81, 3.11% lower than the previous day. Investors should research the company’s fundamentals and review past and recent financials before taking a position in the stock.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
